Figure 3.

The effects of pharmacological inhibition of ACSL4 by Rosi on the development of RM after EHS onset. (A) The expression levels of ACSL4 and GPX4 in EHS mice were detected using the western blotting test. The representative western blotting images were from three independent experiments. Rosi (0.4 mg/kg, intravenous injection, 2 h before EHS experiment) was administered to mice. All samples were collected at 6 h after EHS onset. (B) Representative H&E staining and Evans blue fluorescence of Gas muscle slices were imaged by microscopy (scale bar = 50 μm in H&E, 200 μm in Evans blue testing image). (C) The fibre injury score in EHS mice with or without Rosi treatment (n = 6 mice/group). (D) The degree of permeability in muscle cells was detected by measuring the quality of EBD permeating into muscle cells under standard concentration curve (n = 6 mice/group). (E) The grip strength test in each group (n = 10 mice/group). (F) GPX4 and COX2 protein levels were assessed by western blotting, muscle tissues were collected at 6 h after EHS onset, the representative images of western blotting were from three independent experiments. (G–J) In parallel serum CK levels and MB levels, Gas muscles levels of MDA and 5‐HETE were measured in each groups (n = 6 mice/group). Summary data are presented as the mean ± SEM. Significance was calculated using a one‐way ANOVA with Tukey's post hoc test; groups labelled with different letters differed significantly (*P < 0.05).